Literature DB >> 24997045

The future of probiotics for disorders of the brain-gut axis.

Eamonn M M Quigley1, Fergus Shanahan.   

Abstract

Probiotics, or at the very least products that might have probiotic properties, have been with us for decades, if not centuries, but it has only been in recent years that they have been subjected to serious scientific study. This surge in interest in probiotics has coincided with the era of the microbiome; as more and more is understood about the gut microbiota in health and disease, the therapeutic option of modulating the microbiota through the administration of probiotics has gained a more secure foundation. Regrettably, while a vast literature attests to the beneficial impact of probiotics in a variety of animal models and the mechanisms underlying such positive effects have been dissected in great detail, the data base on probiotics in man remains pretty slender.To make progress, a number of basic issues need to be addressed: strain characterization and other aspects of quality control need to be rigorously applied and additional steps such as dose optimization, definition of desired site of effect and tailoring of formulation accordingly accomplished before large scale trials, based on appropriately selected study endpoints and employing a clinically meaningful study duration, are embarked upon. Meantime, it is to be hoped that the regulatory climate will have been clarified and appropriate guidelines for the evaluation of probiotics, whether as food or drug, developed. Ultimately, the current terminology may have to be abandoned as evidence for biological and clinical activity for dead bacteria, bacterial components and bacterial products accumulates.

Entities:  

Mesh:

Year:  2014        PMID: 24997045     DOI: 10.1007/978-1-4939-0897-4_19

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  6 in total

1.  [Lactobacillus rhamnosus GG conditioned medium prevents E. coli meningitis by inhibiting nuclear factor-κB pathway].

Authors:  Qing Zeng; Xiao-Long He; Han-Sheng Xiao; Lei Du; Yu-Jing Li; Le-Cheng Chen; Hui-Wen Tian; Sheng-He Huang; Hong Cao
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2017-01-20

Review 2.  Probiotics for people with hepatic encephalopathy.

Authors:  Rohan Dalal; Richard G McGee; Stephen M Riordan; Angela C Webster
Journal:  Cochrane Database Syst Rev       Date:  2017-02-23

Review 3.  Natural environments, ancestral diets, and microbial ecology: is there a modern "paleo-deficit disorder"? Part II.

Authors:  Alan C Logan; Martin A Katzman; Vicent Balanzá-Martínez
Journal:  J Physiol Anthropol       Date:  2015-03-10       Impact factor: 2.867

4.  A randomized placebo-controlled clinical trial of a multi-strain probiotic formulation (Bio-Kult®) in the management of diarrhea-predominant irritable bowel syndrome.

Authors:  Shamsuddin M Ishaque; S M Khosruzzaman; Dewan Saifuddin Ahmed; Mukesh Prasad Sah
Journal:  BMC Gastroenterol       Date:  2018-05-25       Impact factor: 3.067

5.  The Conditioned Medium of Lactobacillus rhamnoides GG Regulates Microglia/Macrophage Polarization and Improves Functional Recovery after Spinal Cord Injury in Rats.

Authors:  Fangqi Lin; Baokun Zhang; Qiang Shi; Jiaming Liang; Xin Wang; Xiaofeng Lian; Jianguang Xu
Journal:  Biomed Res Int       Date:  2021-07-10       Impact factor: 3.411

6.  Screening of antagonistic strains of respiratory origin and analysis of their bacteriostatic effects on pathogens.

Authors:  Xinming Li; Biao Yang; Ye Sun; Shuyin Li; Defeng Liu; Yang Zou; Chunling Xiao
Journal:  Microbiologyopen       Date:  2019-10-06       Impact factor: 3.139

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.